Figure 2: Recurrent genetic alterations in pancreatic cancer and their effect on disease outcome. | Nature Communications

Figure 2: Recurrent genetic alterations in pancreatic cancer and their effect on disease outcome.

From: Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients

Figure 2

(a) Representation of the mutations identified in chromatin modifying and other recurrently mutated genes. Each patient sample is indicated as a grey box with mutations indicated in green or black. (b) Analyses of overall survival revealed that patients wild type for MLL gene alterations (n=87) had a significantly lower median survival compared with those with mutated MLL genes (n=14; median survival 15.3 months versus not reached respectively, P=0.0063, log-rank test). (c) Similar analyses revealed significantly improved survival in patients with mutations in either MLL or ARID1A genes (n=20) compared with those that were wild type for any of these genes (n=81).

Back to article page